BPC-157: What's Actually Been Tested, and How

The short version

BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide derived from a piece of a protein found in human gastric juice. In animal studies it accelerates healing of tendons, ligaments, gut lining, and blood vessels, largely by promoting the growth of new blood vessels (angiogenesis) ^[4]. In humans, the evidence is much thinner: as of 2025, only three small pilot studies exist, and a first-in-human intravenous safety trial in two adults found no adverse effects at doses up to 20 mg ^[1][2]. There is no large, controlled human trial establishing that BPC-157 works for anything.

BPC-157 is not an approved drug. It is sold as a research chemical, and in 2023 the FDA specifically excluded it from the list of substances eligible for pharmacy compounding. This page covers what the animal and pilot-human research actually shows, what it doesn't, and what's reported anecdotally — never a dose to take.

What it is

BPC-157 is a synthetic 15-amino-acid peptide (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, molecular formula C62H98N16O22) derived from a partial sequence of a protein found in human gastric juice, which is where the name "Body Protection Compound" comes from. It's often described in the research literature as a "stable gastric pentadecapeptide" — a fifteen-residue chain studied mostly by injection in laboratory animals.

The first formal pharmacokinetic characterization used intramuscular dosing in rats and dogs and found an elimination half-life under 30 minutes and modest intramuscular bioavailability — roughly 14-19% in rats and 45-51% in dogs — with the peptide broken down into small fragments that enter normal amino-acid metabolism and excreted via urine and bile ^[3]. That is injectable-route data. No comparable pharmacokinetic study has been published for oral, sublingual, or transdermal BPC-157 in any species.

How it works

BPC-157's repair effects in animal models are most consistently tied to angiogenesis — the growth of new blood vessels. The best-characterized pathway is up-regulation and internalization of the VEGFR2 receptor, with downstream VEGFR2-Akt-eNOS (nitric oxide) signaling that drives new vessel formation; blocking the internalization step blocks the effect ^[4]. Other reported routes include the FAK-paxillin complex (involved in cell migration), growth-hormone-receptor sensitization in tendon fibroblast cultures, and effects on the nitric-oxide system and several neurotransmitter systems.

None of this mechanistic work has been done in living humans — it comes from cell cultures, chick membrane assays, and rodent injury models. How faithfully that translates to a person, by any route, is unresolved.

What the research shows

Human safety pilot (IV). The only dedicated human safety study on record gave intravenous BPC-157 up to 20 mg to two healthy adults (a 58-year-old man and a 68-year-old woman). It was well tolerated, with no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid, or glucose biomarkers ^[1]. This is a two-person pilot, not an efficacy trial, and it used the intravenous route — not oral, sublingual, or subcutaneous.

State of the human literature. A 2025 narrative review states plainly that despite broad preclinical support, human data remain extremely limited — "only three pilot studies have examined BPC-157 in humans" — and that rigorous, large-scale trials are lacking. The review recommends treating BPC-157 as investigational and using caution given its regulatory status and non-regulated availability ^[2].

Pharmacokinetics (animal, intramuscular). BPC-157 shows linear pharmacokinetics in rats and beagle dogs after intramuscular dosing, with a very short elimination half-life (under 30 minutes), modest IM bioavailability, and rapid breakdown into small peptide fragments that enter ordinary amino-acid metabolism ^[3].

Angiogenesis mechanism. In chick membrane, rat hindlimb-ischemia, and human endothelial-cell models, BPC-157 up-regulated VEGFR2 and promoted its internalization, increasing vessel density and accelerating blood-flow recovery in ischemic muscle — an effect blocked when endocytosis was inhibited ^[4].

Foundational cytoprotection finding. In Wistar rats, BPC-157 reduced gastric ulcer area and accelerated healing, with intramuscular delivery outperforming intragastric (oral-route) delivery in the same experiment — an early, direct signal that route affects outcome for this molecule ^[5].

Reported effects, cautions & safety

People in research-use communities describe a consistent set of experiences with BPC-157. These come from forums, clinic write-ups, and qualitative reviews of online reports — they are anecdotal, not clinical evidence, and none of them specify a route-controlled dose.

Reported benefits: The most common report is faster-feeling recovery from tendon, ligament, and joint injuries — old sprains, tennis elbow, rotator-cuff strain — often described as improving within one to three weeks. Reduced joint stiffness and pain, and improved digestive symptoms (less bloating, cramping, better food tolerance) are also frequently mentioned, again typically in the first one to two weeks. Smaller numbers of users describe faster skin and wound healing, a general sense of reduced inflammation, and better sleep or mood — the last of these is hard to separate from pain or gut improvement, and from placebo.

Reported adverse effects: The most common complaint by far is a local injection-site reaction — brief stinging, redness, or a small bump that typically fades within a day. That alone is a reminder that most of these community reports come from an injectable route, not oral or sublingual products. Mild nausea or stomach upset is reported more often with oral or sublingual products than with injections. Fatigue, headache, dizziness, transient flushing, and, rarely, heart palpitations round out the less-common complaints.

Cited cautions from the literature:

• The human evidence is extremely thin. Almost everything known comes from rodents; only a handful of small, uncontrolled human reports exist, and large controlled trials are lacking ^[1][2][3][4].
• Much of the foundational work comes from one research group, limiting independent replication ^[2].
• Not an approved drug; unregulated products vary in identity and purity outside formal studies ^[2].
• Strong pro-angiogenic activity is a theoretical concern in active or suspected cancer, since tumors also depend on new blood vessels ^[4].
• Possible interaction with serotonin-affecting medicines, based on animal work showing altered serotonin activity — theoretical, not established in humans.
• It promotes growth signaling in tendon cells, and long-term effects of that are unknown.
• Banned in competitive sport by the World Anti-Doping Agency.
• Unstudied in pregnancy, breastfeeding, and children.

Where it fits in delivery-route research

BPC-157 is the clearest illustration on this desk of route mattering as much as compound. Every human safety datapoint comes from an intravenous pilot ^[1]; every formal pharmacokinetic number comes from intramuscular dosing in animals, where it consistently outperformed the oral (intragastric) route in the same rat experiments ^[3][5]. Products marketed as oral capsules or sublingual troches are extrapolating from that injectable evidence base, not extending it — no published study has measured how much of an oral or sublingual BPC-157 dose actually survives to reach circulation in a human. CJC-1295 tells a similar story from the growth-hormone axis; semaglutide is the one member of this trio where an oral route has actually been engineered and measured. See the comparison page for the route-by-route breakdown.